A total of 102 women with recurrent urinary tract infections were included in this open randomized study; 55 received 200 mg of norfloxacin daily and 47 received 50 mg of nitrofurantoin daily over 6 months. Fifty-three and 41 women from the norfloxacin-and nitrofurantoin-treated groups, respectively, completed the 6-month follow-up period. Forty-four (81%) of the norfloxacin-treated patients and 27 (65%) of the nitrofurantointreated patients remained free of symptoms (P = 0.05), and urine samples from 49 (92.4%) and 29 (70.7%) of the patients, respectively, were sterile (P < 0.005). Side effects occurred with similar frequencies in both groups (15 and 17%) but were more severe in the women who received nitrofurantoin. Despite the better results obtained with norfloxacin, the difference in the costs of the two agents must be considered.
Recurrent urinary tract infection (UTI) is a common problem affecting approximately 6 to 10% of women of all ages. Most of those affected have a normal urogenital tract, and most of the infections are caused by recurrent colonization of the periurethral area by microorganisms from the intestinal flora with subsequent ascension to the bladder (6) .
Effective antibiotic regimens to prevent recurrent UTIs have used low doses of trimethoprim-sulfamethoxazole, trimethoprim alone, nitrofurantoin, and cephalosporins over a prolonged period of time (5) .
The new fluoroquinolones are ideal agents for the treatment of UTIs because of their broad-spectrum activity against most uropathogens and their ability to achieve high levels in the urinary tract. Numerous studies have shown their efficacy in the treatment of complicated and uncomplicated UTIs (1, 7), but few studies have evaluated their effectiveness as prophylactic agents (3, 4 Forty-four (81%) women in the norfloxacin-treated group and 27 (65%) in the nitrofurantoin-treated group remained free of symptoms (P = 0.05), and the urine samples of 49 (92.4%) and 29 (70.7%) of the women, respectively, were sterile (P c 0.005). The incidence of UTIs after initiation of prophylaxis dropped dramatically in both groups, from 3.1 episodes per 6 months before treatment to 0.02 episode per 6 months after prophylaxis for the norfloxacin-treated women and from 3 episodes per 6 months to 0.3 episode per 6 months for the nitrofurantoin-treated women (P < 0.005) ( Table 2) .
Side effects from the medications occurred with similar frequencies in both groups (15 and 17% for the norfloxacinand nitrofurantoin-treated women, respectively) but were more severe among the women who received nitrofurantoin, leading to discontinuation of the drug for four women (Table  3) . No organisms resistant to norfloxacin were found, but in two women treated with nitrofurantoin, resistant uropathogens appeared.
During the study period no hematological, liver, or kidney abnormalities developed.
The efficacy of a prophylactic antimicrobial regimen in women with recurrent UTI is based on two mechanisms: (i) the eradication of members of the family Enterobacteriaceae from the intestine and the vagina, as occurs with treatment with trimethoprim-sulfamethoxazole, and (ii) intermittent sterilization of the urine, as is observed with treatment with nitrofurantoin (3).
Norfloxacin, like other fluoroquinolones, produces both effects. Nicolle et al. reported a 1-year comparative study of the effects of 200 mg of norfloxacin given daily versus those of a placebo on women with recurrent UTI (3). They demonstrated that norfloxacin was indeed effective in suppressing growth of members of the family Enterobacteriaceae in rectal cultures and that it also achieved bactericidal levels in the bladder, resulting in intermittent sterilization of the urine. This study confirms the high efficacy and safety of a 200-mg dose of norfloxacin taken daily for 6 months in the prevention of recurrent UTI in women. Previous data have shown that trimethoprim-sulfamethoxazole taken three times weekly was also highly effective (4) . We presume that norfloxacin might also be effective in a lower-frequency dosage. Control studies are needed to test this possibility.
Because of the higher cost of the fluoroquinolones, we recommend reserving their use for women with UTIs with multiresistant organisms, for patients exhibiting intolerance, or for women for whom use of nitrofurantoin or trimethoprim-sulfamethoxazole has failed.
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